Fresenius Medical Care AG & Co. KGaA risk profile
50 Elevated one input has moved against it
Measured 21 October 2026 from FMS's filed statements. Recomputed nightly.
50 (Elevated), driven by Competitive position at 73, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 36 | Normal | Stable | One-year price volatility — 30.3% |
| Operating pressure | 35 | Normal | Easing | Costs outgrowing revenue — -1.9 percentage points |
| Cash conversion | 21 | Normal | Stable | Capital spending against operating cash — 0.34x |
| Leverage and coverage | 39 | Normal | Stable | Net debt to EBITDA — 2.71x |
| Competitive position | 73 | Stretched | Stable | Revenue-growth gap against peers — -28.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Fresenius Medical Care AG & Co. KGaA